coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    St Helens North PCN, St. Helens (LAD) · Health Inequalities Profile

    PCN U94037 · NHS Cheshire and Merseyside Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    30,151

    Registered population

    57.1% aged 18–64

    25.5%

    Aged 65+

    ICB 19.0% · England 17.9%

    2.5%

    Ethnic minority (non-White)

    0.9% Asian · England 9.6%

    9.5%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~3,701

    Core20 residents (est.)

    Resident basis; registered basis ~3,784 · see page 3

    6,373

    Hypertension register

    +7.18% in 3 yrs · England +5.60%

    272

    SMI register

    12% of St. Helens (LAD)'s

    701

    COPD register

    Reviews +5.02% in 3 yrs

    Forecast to 2030

    7,601

    Hypertension patients, 2030

    +1,228 on today

    71.6%

    QRISK ≥20% on statins, 2030

    +5.22pp over 3 yrs

    6.3%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -11.0 pp
    SMI physical health checks fell over three years.

    Over 2023 to 2025, psychosis alcohol recording fell 11.0 pp to 76.5% (England +5.4 pp), alongside BMI (-8.1 pp) and BP (-7.4 pp).

    59.6%
    High-risk lipid therapy trails national and local benchmarks.

    Patients with QRISK ≥ 20% on lipid-lowering therapy reached 59.6% (England 63.6%), alongside 8,640 lipid items per 1,000 aged 65+ (England 18,056 rate).

    75.3%
    Hypertension blood pressure control exceeds all comparators.

    Hypertension patients treated to target reached 75.3% against 69.3% in St. Helens (LAD) and 70.3% in England, rising +8.3% over 2023 to 2025.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Registered patients aged 65+ reach 25.5%, exceeding England by 7.6 percentage points

    Across 30,151 registered patients, 25.5% (7,691) are aged 65+, above St. Helens (LAD) (20.1%), NHS Cheshire and Merseyside Integrated Care Board (19.0%), and England (17.9%). Adults aged 18–64 comprise 57.1% (LAD 61.1%, ICB 61.9%, England 62.7%) and children aged 0–17 represent 17.4% (LAD 18.7%, ICB 19.2%, England 19.6%). Projected list growth to 2030 is 2.4% (unverified methodology). Census usual residents in associated areas are 97.5% White (LAD 96.5%, ICB 93.0%, England 81.1%), leaving a 2.5% ethnic minority share.

    Age profile

    0–1717.4%
    18–6457.1%
    65+25.5%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White97.5%
    Mixed0.9%
    Asian0.9%
    Other0.4%
    Black0.3%

    Older people · falls rows are St. Helens (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (St. Helens LA)2,2082,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)86.8%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.5%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (St. Helens LA)1,1431,0219552024/25
    Falls deaths, all ages, per 100,000 (St. Helens LA)24.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 9.5% overall but concentrated entirely within two practices

    The PCN Core20 cohort is 9.5%, below St. Helens (LAD) (38.5%), NHS Cheshire and Merseyside Integrated Care Board (31.9%), and England (21.0%), with an average IMD decile of 6.1. A 3.03 percentage point reconciliation difference exists between the PCN rate and the 12.5% weighted practice share. Core20 workload is concentrated at Windermere Medical Centre (57.7%, 2,256 estimated patients) and Bethany Medical Centre (35.9%, 1,528 estimated patients), while four practices record 0.0%. Targeted outreach and Core20 resources can focus on these two practices where identified workload resides.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Windermere57.7% · 2,256 patients
    Bethany35.9% · 1,528 patients
    Billinge Medical0.0% · 0 patients
    Rainford0.0% · 0 patients
    Kenneth Macrae0.0% · 0 patients
    Garswood0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    272

    SMI register

    0.92% recorded prevalence

    138

    Learning disability register

    0.47% recorded prevalence

    13

    Care homes, 334 beds

    In the PCN catchment

    11.7%

    Provide unpaid care

    St. Helens (LAD), Census 2021

    Recorded learning disability prevalence is 0.5% (138 patients; St. Helens (LAD) 0.6%, NHS Cheshire and Merseyside ICB 0.6%, England 0.6%) and severe mental illness is 0.9% (272 patients; LAD 1.1%, ICB 1.1%, England 1.0%). The catchment includes 13 care homes with 334 beds.

    Severe mental illness: physical health checks

    Over 2023 to 2025, recorded SMI checks fell 11.0 pp for alcohol (England +5.4 pp), 8.1 pp for BMI (England +5.1 pp), and 7.4 pp for blood pressure (England +4.4 pp), which could reflect worsening recall or coding.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    6,373

    Hypertension register

    +7.18%

    Register growth, 3 yrs

    St. Helens (LAD) +5.27% · England +5.60%

    +4.68pp

    BP control, under 80

    ≤140/90 · +2.66pp aged 80+

    +1,228

    More patients by 2030

    Forecast 7,601 (24.68%)

    Hypertension case-finding and control

    Hypertension QOF prevalence is 21.5% (6,373 patients), above England (15.2%), St. Helens (LAD) (18.7%), and NHS Cheshire and Merseyside Integrated Care Board (16.8%). Over 2023 to 2025, prevalence grew +1.4 pp (+7.2%, England +0.8 pp). Blood pressure control is strong: 75.3% are treated to target (England 70.3%), and 71.7% aged under 80 achieve <= 140/90 mmHg (England 67.8%). Across practices, recorded prevalence spans from 14.7% at Windermere Medical Centre to 25.9% at Rainford Health Centre. Crude prevalence does not establish undiagnosed disease, and the implied base (29,669) differs from the 30,151 list. Blood pressure control exceeds England, but recorded prevalence varies across practices, suggesting case-finding should be prioritized where prevalence is lowest.

    Lipids and statins

    Lipid-lowering therapy for QRISK ≥ 20% reaches 59.6%, trailing England (63.6%), St. Helens (LAD) (62.1%), and NHS Cheshire and Merseyside Integrated Care Board (63.2%). In patients aged 65+, lipid prescribing is 8,640 per 1,000 (England 18,056 rate). Fewer at-risk patients receive lipid-lowering therapy than England implies, prioritizing primary prevention recall audits.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202666,447£1.60£1.71£1.86£106,315
    Cardiovascular (all), 2025101,829£4.15£4.37£3.33£422,590

    In 2026, 66,447 items of lipid-modifying drugs were prescribed at £1.60 per item, below England (£1.86), St. Helens (LAD) (£1.75), and NHS Cheshire and Merseyside Integrated Care Board (£1.71). PCN spend was £17,276 less than at England's unit cost. Spending less per item than England offers headroom to expand lipid therapy to under-treated cohorts.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +1.61%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +3.51%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.9% (2,526 patients), above England (6.6%), St. Helens (LAD) (8.2%), and the ICB (7.0%). Prescribed asthma management items for ages 5–19 reached 2,691 per 1,000 (England 1,488 rate). Over 2023 to 2025, asthma reviews rose +1.6% to 68.5%, trailing England's +4.4% growth and leaving 796 unreviewed on the register scale. COPD prevalence is 2.4% (701 patients), above England (1.9%) but below the borough (2.9%), while COPD reviews reached 80.6% (England 76.4%). Slower review growth alongside high prescribing suggests proactive asthma review recall could be prioritised.

    Cancer register and children's immunisation

    The cancer register records 1,494 patients (5.0%, above England 3.8%). In Q1 2025/26, age-5 MMR1 reached 98.3%, exceeding the 95.0% target. However, age-5 MMR2 was 91.5% (a 6.8 pp difference), the 4-in-1 booster was 86.4% (8.6 pp below target), and 24-month MMR1 reached 87.9% (7.1 pp below target). Slower pre-school booster completion indicates second-dose and booster follow-up could be prioritised.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months90.6%

    England 91.0%

    6-in-1 complete primary course at 24 months89.7%

    England 92.2%

    MMR dose 1 at 24 months87.9%

    England 88.3%

    MMR dose 2 at age 591.5%

    England 82.8%

    4-in-1 pre-school booster at age 586.4%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    At ICB level (wider system data, not PCN performance), in 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (7,482 of 13,490 known-stage cases; England 55.3%), below the 75.0% national ambition by 19.5 pp. Known stage was recorded for 72.8% of cases (13,490 of 18,522 registered cancers; England 67.0%), requiring about 2,640 additional early-stage diagnoses annually across the ICB to reach the ambition. Across ST HELENS NORTH PCN, cancer prevalence is 5.0% (1,494 patients). While PCN cervical screening reaches 76.3% (England 66.8%), coverage is 67.1% at Windermere Medical Centre.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At provider level (wider system data, not PCN performance), in provisional July 2026 data, Mersey and West Lancashire Teaching Hospitals NHS Trust met the 62-day cancer standard for 78.0% of pathways (England 71.2%, ICB 76.2%), below the 85.0% standard by 7.0 pp. The trust achieved 72.4% on the 28-day faster diagnosis standard (standard 75.0%), behind Liverpool University Hospitals NHS Foundation Trust (75.5%) and Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (82.8%). In diagnostics, 23.3% of patients waited 6+ weeks for non-obstetric ultrasound (England 19.6%), and 14.0% for MRI.

    Pathways within standard (%)Mersey and West LancashireWrightington, Wigan and LeighLiverpoolCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)72.3982.8075.4777.2579.32
    31-day treatment (96%)95.4689.0490.5195.7192.50
    62-day referral to treatment (85%)77.9676.7873.2676.2371.16
    Diagnostic waits over 6 weeks (%)Mersey and West LancashireWrightington, Wigan and LeighLiverpoolEngland
    MRI14.040.496.4221.40
    CT13.087.780.719.92
    Echocardiography34.8824.3712.5528.48
    Colonoscopy18.046.1033.1430.83
    Gastroscopy18.1712.5444.9929.02
    All 15 DM01 tests21.1714.3611.5023.14
    Community services activitySt. Helens residentsCheshire and Merseyside ICB
    Care contacts48,525541,280
    Referrals7,81597,150
    Patients with a contact12,745146,240

    Community services (residents of St. Helens), Jun 2026 (provisional). At borough level (wider system data, not PCN performance), in provisional June 2026 data from the Community Services Dataset, 59.9% of community contacts for St. Helens borough residents were with adults aged 65 and over (29,090 of 48,525 contacts). With 25.5% of PCN registered patients aged 65+, intermediate care and district nursing provide key infrastructure for post-diagnostic monitoring and local palliative support.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Vaccination achievement varies by 66.5 pp across captured practices

    Across captured practices, the range in QOF vaccination and immunisation-domain achievement is 66.5 pp. In 2025/26, Windermere Medical Centre recorded 23.9% (England 55.2%), while Bethany Medical Centre reached 90.4%. In overall QOF achievement for 2025/26, Windermere Medical Centre achieved 91.4% and Bethany Medical Centre achieved 97.1% (England 92.5%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Kenneth Macrae1140.092.4%66.3%97.7%
    Rainford1000.089.6%73.5%96.9%
    Windermere10757.783.3%83.6%93.0%
    Billinge Medical1230.078.3%79.6%92.8%
    Bethany10835.985.2%78.4%86.5%
    Garswood Surgery1140.084.5%69.6%78.4%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNSt. Helens (LAD)AssetPCNSt. Helens (LAD)
    Care homes (catchment)13 (334 beds)n/aSchools (catchment)43n/a
    Children's centres18Places of worship3990
    Libraries415Primary schools (LA maintained)1532
    Primary academies311Special schools12

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    SMI physical health check recall

    Over 2023 to 2025 across the 272-patient SMI register, alcohol recording fell 11.0 pp to 76.5% (England +5.4 pp), BMI fell 8.1 pp to 76.5% (England +5.1 pp), and BP fell 7.4 pp to 83.2% (England +4.4 pp). Moderate effort to run.

    Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.

    Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.

    Option 2

    Pre-school booster and MMR2 recall

    In Q1 2025/26 (cohort 59), age-5 MMR1 is 98.3%, while MMR2 is 91.5% (6.8 pp difference; 3.5 pp below the 95.0% target) and the 4-in-1 booster is 86.4% (8.6 pp below target). For discussion: run targeted pre-school recall for children missing MMR2 or the 4-in-1 booster, offering flexible clinic slots. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 3

    Structured asthma review recall

    Asthma prevalence is 8.9% (2,526 patients; England 6.6%), while 2023 to 2025 review growth (+1.6% to 68.5%) trailed England (+4.4%), leaving 796 patients (about 800) unreviewed on the register scale. For discussion: run a single-template asthma recall prioritising repeat inhaler prescriptions, offering after-school slots for children. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Targeted Core20 practice outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check audit (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Targeted hypertension case finding (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · SMI physical health check recall (p12)Severe mental illness register · Patients with psychosis who have a current record of alcohol consumption · Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Option 2 · Pre-school booster and MMR2 recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 3 · Structured asthma review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15